Apis Mellifera Arabica Coffee Bean Arsenic Trioxid

證據等級: L5

預測適應症: 0 個

Multi-Ingredient Homeopathic Complex: Unclassified Indication to No Predicted Indication

One-Sentence Summary

This product is a complex multi-ingredient preparation comprising 25 components — including classical homeopathic substances such as Nitroglycerin, Digitalis, Atropa belladonna, Arsenic trioxide, and multiple venoms — with no registered indication in the Taiwan regulatory database. The TxGNN model returned no predicted new indications for this entry, and accordingly no supporting clinical trials or publications are available for repurposing evaluation. Without an identifiable single active ingredient, a valid DrugBank entry, or any regulatory approval record, this candidate cannot proceed through standard drug repurposing assessment at this time.

Quick Overview

Item	Content
Original Indication	Not available (no regulatory record)
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	Below L5 (no predictions, no actual studies)
Taiwan Market Status	✗ Not marketed
Number of NDA Licenses	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No repurposing prediction is available for this candidate. The entry consists of 25 heterogeneous ingredients spanning botanical extracts (Hypericum perforatum, Black Cohosh, Bryonia alba), animal-derived venoms (Crotalus horridus, Lachesis muta, Naja naja, Micrurus corallinus, Vipera berus), classical cardioactive substances (Digitalis, Nitroglycerin, Convallaria majalis), and toxic alkaloid sources (Strychnos nux-vomica, Atropa belladonna, Gelsemium sempervirens). This combination profile is characteristic of a complex homeopathic preparation.

TxGNN’s knowledge graph and deep learning pipeline are designed for single-entity active pharmaceutical ingredients (APIs) mapped to a DrugBank ID. Because this product has no resolvable DrugBank ID and is composed of dozens of heterogeneous constituents, the model could not identify a valid node in the knowledge graph, and the prediction pipeline produced no output.

Currently, detailed mechanism of action data is not available. Based on known information, several individual components (Digitalis, Nitroglycerin) have well-characterised cardiac mechanisms, while others (homeopathic dilutions of venoms) lack conventional pharmacological characterisation. Any repurposing evaluation would need to be scoped to individual constituents rather than the combination product as a whole.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Taiwan Market Information

This product is not registered in the Taiwan regulatory database. No NDA, license, or market authorisation record was found in the TFDA query conducted on 2026-03-24.

Safety Considerations

Please refer to the package insert for safety information.

Note: Several individual ingredients in this product are classified as highly toxic in conventional medicine contexts — including Arsenic trioxide (WHO Group 1 carcinogen), Atropa belladonna (anticholinergic toxidrome risk), Digitalis (narrow therapeutic index), and Strychnos nux-vomica (strychnine source). If this product is evaluated further, ingredient-level safety assessment is strongly advised before any clinical application.

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate does not meet the minimum requirements for a drug repurposing evaluation — there is no single resolvable active ingredient, no DrugBank mapping, no TxGNN prediction, and no regulatory approval in any jurisdiction. The multi-ingredient homeopathic profile is architecturally incompatible with the current TxGNN pipeline, which operates at the single-molecule level.

To proceed, the following is needed:

Decompose the product into individual constituents — identify which single ingredient is the intended subject of repurposing analysis (e.g., Nitroglycerin, Arsenic trioxide, or Hypericum perforatum)
Resolve a valid DrugBank ID for the target ingredient before re-submitting to the TxGNN pipeline
Clarify the product’s regulatory context — is this a homeopathic product, a combination OTC, or a multi-component botanical? This determines which regulatory pathway applies
Obtain ingredient-level safety data for the most pharmacologically active components (Digitalis, Arsenic trioxide, Atropa belladonna) before any downstream evaluation
Resubmit as individual drug entries — one Evidence Pack per active ingredient — to obtain meaningful TxGNN predictions
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.